101
|
Ivagnès A, Messaoudene M, Stoll G, Routy B, Fluckiger A, Yamazaki T, Iribarren K, Duong CPM, Fend L, Caignard A, Cremer I, LeCesne A, Adam J, Honoré C, Mir O, Chaigneau L, Berger A, Validire P, Christidis C, Brun-Ly VL, Smyth MJ, Mariette X, Salomon BL, Kroemer G, Rusakiewicz S, Zitvogel L. TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer. Oncoimmunology 2017; 7:e1386826. [PMID: 30524877 DOI: 10.1080/2162402x.2017.1386826] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2017] [Revised: 09/26/2017] [Accepted: 09/26/2017] [Indexed: 01/07/2023] Open
Abstract
Natural Killer (NK) cells control metastatic dissemination of murine tumors and are an important prognostic factor in several human malignancies. However, tumor cells hijack many of the NK cell functional features compromising their tumoricidal activity. Here, we show a deleterious role of the TNFα/TNFR2/BIRC3/TRAF1 signaling cascade in NK cells from the tumor microenvironment (TME). TNFα induces BIRC3/cIAP2 transcripts and reduces NKp46/NCR1 transcription and surface expression on NK cells, promoting metastases dissemination in mice and poor prognosis in GIST patients. NKp30 engagement, by promoting the release of TNFα, also contributes to BIRC3 upregulation, and more so in patients expressing predominantly NKp30C isoforms. These findings reveal that in the absence of IL-12 or a Th1-geared TME, TNFα can be considered as a negative regulatory cytokine for innate effectors.
Collapse
Affiliation(s)
- Alexandre Ivagnès
- Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), Villejuif, France.,INSERM U1015, GRCC, Villejuif, France.,Université Paris Sud, Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France
| | - Meriem Messaoudene
- Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), Villejuif, France.,INSERM U1015, GRCC, Villejuif, France
| | - Gautier Stoll
- INSERM, U1138, Centre de Recherche des Cordeliers, Paris, France.,Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France.,Université Paris Descartes/Paris V, Sorbonne Paris Cité, 15 rue de l'Ecole de Médecine, Paris, France.,Université Pierre et Marie Curie, 15 rue de l'Ecole de Médecine, Paris, France
| | - Bertrand Routy
- Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), Villejuif, France.,INSERM U1015, GRCC, Villejuif, France.,Université Paris Sud, Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France
| | - Aurélie Fluckiger
- Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), Villejuif, France.,INSERM U1015, GRCC, Villejuif, France
| | - Takahiro Yamazaki
- Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA
| | - Kristina Iribarren
- INSERM, U1138, Centre de Recherche des Cordeliers, Paris, France.,Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France.,Université Paris Descartes/Paris V, Sorbonne Paris Cité, 15 rue de l'Ecole de Médecine, Paris, France
| | - Connie P M Duong
- Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), Villejuif, France.,INSERM U1015, GRCC, Villejuif, France
| | | | - Anne Caignard
- INSERM, U1160, Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,Institut Universitaire d'Hématologie, Hôpital Saint Louis, Paris, France
| | - Isabelle Cremer
- INSERM, U1138, Centre de Recherche des Cordeliers, Paris, France.,Université Paris Descartes/Paris V, Sorbonne Paris Cité, 15 rue de l'Ecole de Médecine, Paris, France.,Université Pierre et Marie Curie, 15 rue de l'Ecole de Médecine, Paris, France
| | - Axel LeCesne
- Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), Villejuif, France.,Département d'oncologie médicale, GRCC, Villejuif, France
| | - Julien Adam
- Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), Villejuif, France.,Département d'anatomo-pathologie, GRCC, Villejuif, France.,INSERM U981, GRCC, Villejuif, France
| | - Charles Honoré
- Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), Villejuif, France.,Département de chirurgie, GRCC, Villejuif, France
| | - Olivier Mir
- Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), Villejuif, France.,Département d'oncologie médicale, GRCC, Villejuif, France
| | - Loïc Chaigneau
- Département d'oncologie médicale, Centre Hospitalier Universitaire Jean Minjoz, Besançon, France
| | - Anne Berger
- Université Paris Descartes/Paris V, Sorbonne Paris Cité, 15 rue de l'Ecole de Médecine, Paris, France.,Département de chirurgie, Hôpital Européen Georges Pompidou, Paris, France
| | - Pierre Validire
- Département d'anatomo-pathologie, Institut Mutualiste Montsouris, Paris, France.,Département d'oncologie médicale, Sarcome, Institut Mutualiste Montsouris, Paris, France
| | - Christos Christidis
- Université Paris Descartes/Paris V, Sorbonne Paris Cité, 15 rue de l'Ecole de Médecine, Paris, France.,Département d'oncologie médicale, Sarcome, Institut Mutualiste Montsouris, Paris, France.,Département de chirurgie, Institut Mutualiste Montsouris, Paris, France
| | - Valérie Le Brun-Ly
- Département d'oncologie médicale, Centre hospitalier régional universitaire de Limoges Dupuytren, Limoges, France
| | - Mark J Smyth
- Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia
| | - Xavier Mariette
- Université Paris Sud, Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.,INSERM UMR 1184, Assistance Publique-Hôpitaux de Paris, Service de Rhumatologie, Hôpitaux Universitaires Paris-Sud, Le Kremlin Bicêtre, France
| | - Benoît L Salomon
- Sorbonne Universités, UPMC Univ Paris 06, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Guido Kroemer
- INSERM, U1138, Centre de Recherche des Cordeliers, Paris, France.,Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France.,Université Paris Descartes/Paris V, Sorbonne Paris Cité, 15 rue de l'Ecole de Médecine, Paris, France.,Université Pierre et Marie Curie, 15 rue de l'Ecole de Médecine, Paris, France.,Sorbonne Universités, UPMC Univ Paris 06, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.,Pôle de Biologie, Hôpital Européen Georges Pompidou, Paris, France.,Plateforme de métabolomique et de biologie cellulaire, GRCC,Villejuif, France.,Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden
| | - Sylvie Rusakiewicz
- Center of Experimental Therapeutics, Ludwig Center for Cancer Res, Department of Oncology, University of Lausanne, Lausanne, Switzerland
| | - Laurence Zitvogel
- Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), Villejuif, France.,INSERM U1015, GRCC, Villejuif, France.,Université Paris Sud, Université Paris-Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France.,Centre d'investigation clinique en biothérapie des cancers (CICBT), Villejuif, France
| |
Collapse
|
102
|
Zafeiris D, Vadakekolathu J, Wagner S, Pockley AG, Ball GR, Rutella S. Discovery and application of immune biomarkers for hematological malignancies. Expert Rev Mol Diagn 2017; 17:983-1000. [PMID: 28927305 DOI: 10.1080/14737159.2017.1381560] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
INTRODUCTION Hematological malignancies originate and progress in primary and secondary lymphoid organs, where they establish a uniquely immune-suppressive tumour microenvironment. Although high-throughput transcriptomic and proteomic approaches are being employed to interrogate immune surveillance and escape mechanisms in patients with solid tumours, and to identify actionable targets for immunotherapy, our knowledge of the immunological landscape of hematological malignancies, as well as our understanding of the molecular circuits that underpin the establishment of immune tolerance, is not comprehensive. Areas covered: This article will discuss how multiplexed immunohistochemistry, flow cytometry/mass cytometry, proteomic and genomic techniques can be used to dynamically capture the complexity of tumour-immune interactions. Moreover, the analysis of multi-dimensional, clinically annotated data sets obtained from public repositories such as Array Express, TCGA and GEO is crucial to identify immune biomarkers, to inform the rational design of immune therapies and to predict clinical benefit in individual patients. We will also highlight how artificial neural network models and alternative methodologies integrating other algorithms can support the identification of key molecular drivers of immune dysfunction. Expert commentary: High-dimensional technologies have the potential to enhance our understanding of immune-cancer interactions and will support clinical decision making and the prediction of therapeutic benefit from immune-based interventions.
Collapse
Affiliation(s)
- Dimitrios Zafeiris
- a John van Geest Cancer Research Centre, College of Science and Technology , Nottingham Trent University , Nottingham , United Kingdom
| | - Jayakumar Vadakekolathu
- a John van Geest Cancer Research Centre, College of Science and Technology , Nottingham Trent University , Nottingham , United Kingdom
| | - Sarah Wagner
- a John van Geest Cancer Research Centre, College of Science and Technology , Nottingham Trent University , Nottingham , United Kingdom
| | - Alan Graham Pockley
- a John van Geest Cancer Research Centre, College of Science and Technology , Nottingham Trent University , Nottingham , United Kingdom
| | - Graham Roy Ball
- a John van Geest Cancer Research Centre, College of Science and Technology , Nottingham Trent University , Nottingham , United Kingdom
| | - Sergio Rutella
- a John van Geest Cancer Research Centre, College of Science and Technology , Nottingham Trent University , Nottingham , United Kingdom
| |
Collapse
|
103
|
Mirza AS, Lancet JE, Sweet K, Padron E, Pinilla-Ibarz J, Nardelli L, Cubitt C, List AF, Komrokji RS. A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2017; 17:902-907. [PMID: 29030092 DOI: 10.1016/j.clml.2017.09.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/10/2017] [Accepted: 09/11/2017] [Indexed: 12/19/2022]
Abstract
INTRODUCTION No standard salvage chemotherapy regimen is available for relapsed or refractory (RR) acute myeloid leukemia (AML). Preclinical data have suggested synergy in vitro between cytarabine and imatinib mesylate (IM) on AML cell growth inhibition. After demonstrating the safety and feasibility in a phase I study, we conducted a phase II clinical study of CLAG (cladribine, cytarabine, granulocyte colony-stimulating factor) regimen combined with IM for patients with RR-AML. PATIENTS AND METHODS We performed a single-institution 2-stage phase II study. The primary endpoint was the remission rate measured using the standard AML response criteria. The secondary endpoints included overall survival (OS) and progression-free survival (PFS). RESULTS From August 2009 to April 2011, 38 patients were treated at the Moffitt Cancer Center. Their median age was 62 years (range, 26-79 years). Of the 38 patients, 7 (18%) had refractory AML, 19 (50%) had early relapse, and 12 (32%) had late relapse. At the original diagnosis, only 2 patients had favorable risk factors, 18 had intermediate risk, and 16 had poor risk; for 2 patients, the karyotype was missing. The overall response rate for all 38 evaluable patients was 37%. The median OS was 11.1 months (95% CI, 4.8-13.4 months), the median PFS was 4.9 months (95% CI, 1.6-11.7 months). Among the responders, 8 of 14 patients subsequently underwent allogeneic hematopoietic cell transplantation. CONCLUSION CLAG plus IM was well tolerated, with encouraging signs of activity in patients with poor-risk AML.
Collapse
Affiliation(s)
- Abu-Sayeef Mirza
- Department of Internal Medicine, University of South Florida, Tampa, FL.
| | - Jeffrey E Lancet
- Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
| | - Kendra Sweet
- Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
| | - Eric Padron
- Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
| | - Javier Pinilla-Ibarz
- Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
| | - Lisa Nardelli
- Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
| | | | - Alan F List
- Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
| | - Rami S Komrokji
- Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
| |
Collapse
|
104
|
Abstract
Immunotherapy is currently the most rapidly advancing area of clinical oncology, and provides the unprecedented opportunity to effectively treat, and even cure, several previously untreatable malignancies. A growing awareness exists of the fact that the success of chemotherapy and radiotherapy, in which the patient's disease can be stabilized well beyond discontinuation of treatment (and occasionally is cured), also relies on the induction of a durable anticancer immune response. Indeed, the local immune infiltrate undergoes dynamic changes that accompany a shift from a pre-existing immune response to a therapy-induced immune response. As a result, the immune contexture, which is determined by the density, composition, functional state and organization of the leukocyte infiltrate of the tumour, can yield information that is relevant to prognosis, prediction of a treatment response and various other pharmacodynamic parameters. Several complementary technologies can be used to explore the immune contexture of tumours, and to derive biomarkers that could enable the adaptation of individual treatment approaches for each patient, as well as monitoring a response to anticancer therapies.
Collapse
|
105
|
Bellora F, Dondero A, Corrias MV, Casu B, Regis S, Caliendo F, Moretta A, Cazzola M, Elena C, Vinti L, Locatelli F, Bottino C, Castriconi R. Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 Macrophages. THE JOURNAL OF IMMUNOLOGY 2017; 199:1516-1525. [PMID: 28701512 DOI: 10.4049/jimmunol.1601695] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/03/2016] [Accepted: 06/11/2017] [Indexed: 12/22/2022]
Abstract
Tyrosine kinase inhibitors (TKIs) are used in the clinical management of hematological neoplasms. Moreover, in solid tumors such as stage 4 neuroblastomas (NB), imatinib showed benefits that might depend on both on-target and immunological off-target effects. We investigated the effects of imatinib and nilotinib on human NK cells, monocytes, and macrophages. High numbers of monocytes died upon exposure to TKI concentrations similar to those achieved in patients. Conversely, NK cells were highly resistant to the TKI cytotoxic effect, were properly activated by immunostimulatory cytokines, and degranulated in the presence of NB cells. In NB, neither drug reduced the expression of ligands for activating NK receptors or upregulated that of HLA class I, B7-H3, PD-L1, and PD-L2, molecules that might limit NK cell function. Interestingly, TKIs modulated the chemokine receptor repertoire of immune cells. Acting at the transcriptional level, they increased the surface expression of CXCR4, an effect observed also in NK cells and monocytes of patients receiving imatinib for chronic myeloid leukemia. Moreover, TKIs reduced the expression of CXCR3 (in NK cells) and CCR1 (in monocytes). Monocytes also decreased the expression of M-CSFR, and low numbers of cells underwent differentiation toward macrophages. M0 and M2 macrophages were highly resistant to TKIs and maintained their phenotypic and functional characteristics. Importantly, also in the presence of TKIs, the M2 immunosuppressive polarization was reverted by TLR engagement, and M1-oriented macrophages fully activated autologous NK cells. Our results contribute to better interpreting the off-target efficacy of TKIs in tumors and to envisaging strategies aimed at facilitating antitumor immune responses.
Collapse
Affiliation(s)
- Francesca Bellora
- Dipartimento di Medicina Sperimentale, Università degli Studi di Genova, 16132 Genoa, Italy
| | - Alessandra Dondero
- Dipartimento di Medicina Sperimentale, Università degli Studi di Genova, 16132 Genoa, Italy
| | | | - Beatrice Casu
- Dipartimento di Medicina Sperimentale, Università degli Studi di Genova, 16132 Genoa, Italy
| | | | - Fabio Caliendo
- Dipartimento di Medicina Sperimentale, Università degli Studi di Genova, 16132 Genoa, Italy
| | - Alessandro Moretta
- Dipartimento di Medicina Sperimentale, Università degli Studi di Genova, 16132 Genoa, Italy; .,Centro di Eccellenza per la Ricerca Biomedica, Università degli Studi di Genova, 16132 Genoa, Italy
| | - Mario Cazzola
- Dipartimento di Medicina Molecolare, Università di Pavia, 27100 Pavia, Italy.,Dipartimento di Onco-Ematologia, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, 27100 Pavia, Italy; and
| | - Chiara Elena
- Dipartimento di Medicina Molecolare, Università di Pavia, 27100 Pavia, Italy
| | - Luciana Vinti
- Dipartimento di Onco-Ematologia Pediatrica, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Pediatrico Bambino Gesù, 00146 Rome, Italy
| | - Franco Locatelli
- Dipartimento di Medicina Molecolare, Università di Pavia, 27100 Pavia, Italy.,Dipartimento di Onco-Ematologia Pediatrica, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Pediatrico Bambino Gesù, 00146 Rome, Italy
| | - Cristina Bottino
- Dipartimento di Medicina Sperimentale, Università degli Studi di Genova, 16132 Genoa, Italy.,Istituto Giannina Gaslini, 16148 Genoa, Italy
| | - Roberta Castriconi
- Dipartimento di Medicina Sperimentale, Università degli Studi di Genova, 16132 Genoa, Italy.,Centro di Eccellenza per la Ricerca Biomedica, Università degli Studi di Genova, 16132 Genoa, Italy
| |
Collapse
|
106
|
C 21 -steroidal pregnane sapogenins and their derivatives as anti-inflammatory agents. Bioorg Med Chem 2017; 25:3512-3524. [DOI: 10.1016/j.bmc.2017.04.045] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2017] [Accepted: 04/29/2017] [Indexed: 01/04/2023]
|
107
|
Rea D, Henry G, Khaznadar Z, Etienne G, Guilhot F, Nicolini F, Guilhot J, Rousselot P, Huguet F, Legros L, Gardembas M, Dubruille V, Guerci-Bresler A, Charbonnier A, Maloisel F, Ianotto JC, Villemagne B, Mahon FX, Moins-Teisserenc H, Dulphy N, Toubert A. Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Haematologica 2017; 102:1368-1377. [PMID: 28522576 PMCID: PMC6643734 DOI: 10.3324/haematol.2017.165001] [Citation(s) in RCA: 100] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2017] [Accepted: 05/08/2017] [Indexed: 12/20/2022] Open
Abstract
Despite persistence of leukemic stem cells, patients with chronic myeloid leukemia who achieve and maintain deep molecular responses may successfully stop the tyrosine kinase inhibitor imatinib. However, questions remain unanswered regarding the biological basis of molecular relapse after imatinib cessation. In IMMUNOSTIM, we monitored 51 patients from the French Stop IMatinib trial for peripheral blood T cells and natural killer cells. Molecular relapse-free survival at 24 months was 45.1% (95% CI: 31.44%–58.75%). At the time of imatinib discontinuation, non-relapsing patients had significantly higher numbers of natural killer cells of the cytotoxic CD56dim subset than had relapsing patients, while CD56bright natural killer cells, T cells and their subsets did not differ significantly. Furthermore, the CD56dim natural killer-cell count was an independent prognostic factor of molecular-relapse free survival in a multivariate analysis. However, expression of natural killer-cell activating receptors, BCR-ABL1+ leukemia cell line K562-specific degranulation and cytokine-induced interferon-gamma secretion were decreased in non-relapsing and relapsing patients as compared with healthy individuals. After imatinib cessation, the natural killer-cell count increased significantly and stayed higher in non-relapsing patients than in relapsing patients, while receptor expression and functional properties remained unchanged. Altogether, our results suggest that natural killer cells may play a role in controlling leukemia-initiating cells at the origin of relapse after imatinib cessation, provided that these cells are numerous enough to compensate for their functional defects. Further research will decipher mechanisms underlying functional differences between natural killer cells from patients and healthy individuals and evaluate the potential interest of immunostimulatory approaches in tyrosine kinase inhibitor discontinuation strategies. (ClinicalTrial.gov Identifier NCT00478985)
Collapse
Affiliation(s)
- Delphine Rea
- INSERM UMRS-1160, Paris, France .,Service d'Hématologie Adulte, Hôpital Saint-Louis, Paris, France.,France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Institut Bergonié, Bordeaux, France
| | - Guylaine Henry
- Laboratoire d'Immunologie et Histocompatibilité, Hôpital Saint-Louis, Paris, France
| | - Zena Khaznadar
- INSERM UMRS-1160, Paris, France.,Institut Universitaire d'Hématologie, Université Paris Diderot-Paris 7, France
| | - Gabriel Etienne
- France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Institut Bergonié, Bordeaux, France.,Service d'Oncologie Médicale, Institut Bergonié, Bordeaux, France
| | - François Guilhot
- France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Institut Bergonié, Bordeaux, France.,INSERM CIC 1402, CHU de Poitiers, France
| | - Franck Nicolini
- France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Institut Bergonié, Bordeaux, France.,Service d'Hématologie Clinique, CHU Lyon Sud, Pierre Bénite, France
| | - Joelle Guilhot
- France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Institut Bergonié, Bordeaux, France.,INSERM CIC 1402, CHU de Poitiers, France
| | - Philippe Rousselot
- France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Institut Bergonié, Bordeaux, France.,Service d'Hématologie Oncologie et INSERM UMR-1173, Centre Hospitalier de Versailles, Le Chesnay, France
| | - Françoise Huguet
- France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Institut Bergonié, Bordeaux, France.,Service d'Hématologie, IUCT Oncopole, Toulouse, France
| | - Laurence Legros
- France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Institut Bergonié, Bordeaux, France.,Service d'Hématologie Clinique, Hôpital de l'Archet, CHU de Nice, France
| | - Martine Gardembas
- France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Institut Bergonié, Bordeaux, France.,Service des Maladies du Sang, CHRU Angers, France
| | - Viviane Dubruille
- France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Institut Bergonié, Bordeaux, France.,Service d'Hématologie Clinique, Hôpital Hôtel Dieu, Nantes, France
| | - Agnès Guerci-Bresler
- France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Institut Bergonié, Bordeaux, France.,Service d'Hématologie, CHU Brabois, Vandoeuvre les Nancy, France
| | - Aude Charbonnier
- France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Institut Bergonié, Bordeaux, France.,Service d'Onco-Hématologie, Institut Paoli Calmettes, Marseille, France
| | - Frédéric Maloisel
- Groupe Oncologie-Maladies du Sang, Clinique Sainte Anne, Strasbourg, France
| | | | - Bruno Villemagne
- Service Médecine Onco-hématologie, CH de la Roche sur Yon, France
| | - François-Xavier Mahon
- France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Institut Bergonié, Bordeaux, France.,Service d'Oncologie Médicale, Institut Bergonié, Bordeaux, France
| | - Hélène Moins-Teisserenc
- INSERM UMRS-1160, Paris, France.,Laboratoire d'Immunologie et Histocompatibilité, Hôpital Saint-Louis, Paris, France.,Institut Universitaire d'Hématologie, Université Paris Diderot-Paris 7, France
| | - Nicolas Dulphy
- INSERM UMRS-1160, Paris, France .,Laboratoire d'Immunologie et Histocompatibilité, Hôpital Saint-Louis, Paris, France.,Institut Universitaire d'Hématologie, Université Paris Diderot-Paris 7, France
| | - Antoine Toubert
- INSERM UMRS-1160, Paris, France.,Laboratoire d'Immunologie et Histocompatibilité, Hôpital Saint-Louis, Paris, France.,Institut Universitaire d'Hématologie, Université Paris Diderot-Paris 7, France
| |
Collapse
|
108
|
Coiras M, Ambrosioni J, Cervantes F, Miró JM, Alcamí J. Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection. Expert Opin Drug Saf 2017; 16:547-559. [PMID: 28387147 DOI: 10.1080/14740338.2017.1313224] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
INTRODUCTION Infection caused by HIV-1 is nowadays a chronic disease due to a highly efficient antiretroviral treatment that is nevertheless, unable to eliminate the virus from the organism. New strategies are necessary in order to impede the formation of the viral reservoirs, responsible for the failure of the antiretroviral treatment to cure the infection. Areas covered: The purpose of this review is to discuss the possibility of using tyrosine kinase inhibitors (TKIs) for the treatment of HIV-1 infection. These inhibitors are successfully used in patients with distinct cancers such as chronic myeloid leukemia. The most relevant papers have been selected and commented. Expert opinion: The family of TKIs are directed against the activation of tyrosine kinases from the Src family. Some of these kinases are essential for the activation of CD4 + T cells, the major target of HIV-1. During acute or primary infection the CD4 + T cells are massively activated, which is mostly responsible for the generation of the reservoirs, the spread of the infection and the destruction of activated CD4 + T cells, infected or not. Consequently, we discuss the possibility of using TKIs as adjuvant of the antiretroviral treatment against HIV-1 infection mostly, but not exclusively, during the acute/recent phase.
Collapse
Affiliation(s)
- Mayte Coiras
- a AIDS Immunopathology Unit , National Center of Microbiology, Instituto de Salud Carlos III , Madrid , Spain
| | - Juan Ambrosioni
- b Infectious Diseases Service , AIDS Research Group, Institut d´Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS) , Barcelona , Spain
| | | | - José M Miró
- b Infectious Diseases Service , AIDS Research Group, Institut d´Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS) , Barcelona , Spain
| | - José Alcamí
- a AIDS Immunopathology Unit , National Center of Microbiology, Instituto de Salud Carlos III , Madrid , Spain
| |
Collapse
|
109
|
Hughes A, Yong ASM. Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission. Front Immunol 2017; 8:469. [PMID: 28484463 PMCID: PMC5402174 DOI: 10.3389/fimmu.2017.00469] [Citation(s) in RCA: 80] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2017] [Accepted: 04/05/2017] [Indexed: 01/22/2023] Open
Abstract
Chronic myeloid leukemia (CML) is a hematological cancer, characterized by a reciprocal chromosomal translocation between chromosomes 9 and 22 [t(9;22)], producing the Bcr-Abl oncogene. Tyrosine kinase inhibitors (TKIs) represent the standard of care for CML patients and exert a dual mode of action: direct oncokinase inhibition and restoration of effector-mediated immune surveillance, which is rendered dysfunctional in CML patients at diagnosis, prior to TKI therapy. TKIs such as imatinib, and more potent second-generation nilotinib and dasatinib induce a high rate of deep molecular response (DMR, BCR-ABL1 ≤ 0.01%) in CML patients. As a result, the more recent goal of therapy in CML treatment is to induce a durable DMR as a prelude to successful treatment-free remission (TFR), which occurs in approximately half of all CML patients who cease TKI therapy. The lack of overt relapse in such patients has been attributed to immunological control of CML. In this review, we discuss an immunological timeline to successful TFR, focusing on the immunology of CML during TKI treatment; an initial period of immune suppression, limiting antitumor immune effector responses in newly diagnosed CML patients, linked to an expansion of immature myeloid-derived suppressor cells and regulatory T cells and aberrant expression of immune checkpoint signaling pathways, including programmed death-1/programmed death ligand-1. Commencement of TKI treatment is associated with immune system re-activation and restoration of effector-mediated [natural killer (NK) cell and T cell] immune surveillance in CML patients, albeit with differing frequencies in concert with differing levels of molecular response achieved on TKI. DMR is associated with maximal restoration of immune recovery in CML patients on TKI. Current data suggest a net balance between both the effector and suppressor arms of the immune system, at a minimum involving mature, cytotoxic CD56dim NK cells may be important in mediating TFR success. However, a major goal remains in CML to identify the most effective pathways to target to maximize an advantageous immune response and promote TFR success.
Collapse
Affiliation(s)
- Amy Hughes
- Department of Haematology, SA Pathology, Adelaide, SA, Australia.,Cancer Theme, South Australia Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia.,School of Medicine, The University of Adelaide, Adelaide, SA, Australia
| | - Agnes S M Yong
- Department of Haematology, SA Pathology, Adelaide, SA, Australia.,Cancer Theme, South Australia Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia.,School of Medicine, The University of Adelaide, Adelaide, SA, Australia
| |
Collapse
|
110
|
Milano G. Resistance to immunotherapy: clouds in a bright sky. Invest New Drugs 2017; 35:649-654. [PMID: 28401366 DOI: 10.1007/s10637-017-0456-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2016] [Accepted: 03/15/2017] [Indexed: 01/05/2023]
Abstract
Two major challenges persist for an optimal management of immunotherapy: i) identifying those patients who will benefit from this type of therapy, and ii) determining the biological, cellular and molecular mechanisms that trigger disease progression while on therapy. There is a consensual view in favor of standardizing practices currently used to measure programmed death ligand 1 (PD-L1) expression that relates to innate resistance. The tumor mutation landscape has been widely explored as a potential predictor of treatment efficacy. In contrast, our knowledge is rather limited as concerns the mechanisms sustaining acquired resistance to checkpoint blockade immunotherapy in patients under treatment. Upregulation of T cell immunoglobulin mucin domain 3 (TIM-3) in CD8+ T-cells has been reported in patients developing acquired resistance to anti-PD-1 treatment. Resistance mechanisms are even more complex for combinatorial strategies linking immunotherapeutic agents and conventional therapies, an area that is expanding rapidly. However, with the arrival of advanced analytical methods such as mass cytometry, there is reason for optimism. These methods can identify cellular mechanisms governing response to therapy and resistance. The clinical use of inhibitors of tumor-microenvironment-modulated pathways, such as those targeting indoleamine 2, 3-dioxygenase (IDO), hold promise for resistance management. Graphical abstract Clouds in a bright sky - Joseph Mallord William Turner.
Collapse
Affiliation(s)
- Gérard Milano
- Oncopharmacology Unit, Centre Antoine-Lacassagne, 33 avenue de Valombrose, 06189, Nice Cedex 2, France.
| |
Collapse
|
111
|
Ambrosioni J, Coiras M, Alcamí J, Miró JM. Potential role of tyrosine kinase inhibitors during primary HIV-1 infection. Expert Rev Anti Infect Ther 2017; 15:421-423. [DOI: 10.1080/14787210.2017.1308823] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Juan Ambrosioni
- Infectious Diseases Service, Hospital Clínic, University of Barcelona, Barcelona, Spain
| | - Mayte Coiras
- AIDS Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain
| | - José Alcamí
- AIDS Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain
| | - José M. Miró
- Infectious Diseases Service, Hospital Clínic, University of Barcelona, Barcelona, Spain
| |
Collapse
|
112
|
Nguyen D, Liao W, Zeng SX, Lu H. Reviving the guardian of the genome: Small molecule activators of p53. Pharmacol Ther 2017; 178:92-108. [PMID: 28351719 DOI: 10.1016/j.pharmthera.2017.03.013] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2016] [Accepted: 03/20/2017] [Indexed: 02/07/2023]
Abstract
The tumor suppressor p53 is one of the most important proteins for protection of genomic stability and cancer prevention. Cancers often inactivate it by either mutating its gene or disabling its function. Thus, activating p53 becomes an attractive approach for the development of molecule-based anti-cancer therapy. The past decade and half have witnessed tremendous progress in this area. This essay offers readers with a grand review on this progress with updated information about small molecule activators of p53 either still at bench work or in clinical trials.
Collapse
Affiliation(s)
- Daniel Nguyen
- Department of Biochemistry and Molecular Biology and Tulane Cancer Center, Tulane University School of Medicine, 1430 Tulane Ave, LA 70012, United States
| | - Wenjuan Liao
- Department of Biochemistry and Molecular Biology and Tulane Cancer Center, Tulane University School of Medicine, 1430 Tulane Ave, LA 70012, United States
| | - Shelya X Zeng
- Department of Biochemistry and Molecular Biology and Tulane Cancer Center, Tulane University School of Medicine, 1430 Tulane Ave, LA 70012, United States
| | - Hua Lu
- Department of Biochemistry and Molecular Biology and Tulane Cancer Center, Tulane University School of Medicine, 1430 Tulane Ave, LA 70012, United States.
| |
Collapse
|
113
|
CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood 2017; 129:1166-1176. [DOI: 10.1182/blood-2016-10-745992] [Citation(s) in RCA: 114] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2016] [Accepted: 12/17/2016] [Indexed: 12/12/2022] Open
Abstract
Key Points
Increased immune suppressors and PD-1 abrogates effector responses in CML patients at diagnosis. Enhanced net effector immune responses and decreased PD-1 and immune suppressors may promote sustained deep molecular response in CML.
Collapse
|
114
|
Lopez JS, Banerji U. Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nat Rev Clin Oncol 2017; 14:57-66. [PMID: 27377132 PMCID: PMC6135233 DOI: 10.1038/nrclinonc.2016.96] [Citation(s) in RCA: 211] [Impact Index Per Article: 30.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Our increasing understanding of cancer biology has led to the development of molecularly targeted anticancer drugs. The full potential of these agents has not, however, been realised, owing to the presence of de novo (intrinsic) resistance, often resulting from compensatory signalling pathways, or the development of acquired resistance in cancer cells via clonal evolution under the selective pressures of treatment. Combinations of targeted treatments can circumvent some mechanisms of resistance to yield a clinical benefit. We explore the challenges in identifying the best drug combinations and the best combination strategies, as well as the complexities of delivering these treatments to patients. Recognizing treatment-induced toxicity and the inability to use continuous pharmacodynamically effective doses of many targeted treatments necessitates creative intermittent scheduling. Serial tumour profiling and the use of parallel co-clinical trials can contribute to understanding mechanisms of resistance, and will guide the development of adaptive clinical trial designs that can accommodate hypothesis testing, in order to realize the full potential of combination therapies.
Collapse
Affiliation(s)
- Juanita S Lopez
- Drug Development Unit, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sycamore House, Downs Road, London SM2 5PT, UK
| | - Udai Banerji
- Drug Development Unit, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sycamore House, Downs Road, London SM2 5PT, UK
| |
Collapse
|
115
|
BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors. Blood 2016; 129:582-586. [PMID: 27927646 DOI: 10.1182/blood-2016-07-731091] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2016] [Accepted: 11/29/2016] [Indexed: 12/21/2022] Open
Abstract
Although the emergence of bone marrow (BM)-resident p190BCR-ABL-specific T lymphocytes has been correlated with hematologic and cytogenetic remissions in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) undergoing maintenance tyrosine-kinase inhibitor treatment, little is known about the possibility of culturing these cells ex vivo and using them in T-cell therapy strategies. We investigated the feasibility of expanding/priming p190BCR-ABL-specific T cells in vitro by stimulation with dendritic cells pulsed with p190BCR-ABL peptides derived from the BCR-ABL junctional region and alternative splicing, and of adoptively administering them to patients with relapsed disease. We report on the feasibility of producing clinical-grade BCR-ABL-specific cytotoxic T lymphocytes (CTLs), endowed with antileukemia activity, from Ph+ ALL patients and healthy donors. We treated 3 patients with Ph+ ALL with autologous or allogeneic p190BCR-ABL-specific CTLs. No postinfusion toxicity was observed, except for a grade II skin graft-versus-host disease in the patient treated for hematologic relapse. All patients achieved a molecular or hematologic complete remission (CR) after T-cell therapy, upon emergence of p190BCR-ABL-specific T cells in the BM. Our results show that p190BCR-ABL-specific CTLs are capable of controlling treatment-refractory Ph+ ALL in vivo, and support the development of adoptive immunotherapeutic approaches with BCR-ABL CTLs in Ph+ ALL.
Collapse
|
116
|
Abstract
Fundamental cancer research and the development of efficacious antineoplastic treatments both rely on experimental systems in which the relationship between malignant cells and immune cells can be studied. Mouse models of transplantable, carcinogen-induced or genetically engineered malignancies - each with their specific advantages and difficulties - have laid the foundations of oncoimmunology. These models have guided the immunosurveillance theory that postulates that evasion from immune control is an essential feature of cancer, the concept that the long-term effects of conventional cancer treatments mostly rely on the reinstatement of anticancer immune responses and the preclinical development of immunotherapies, including currently approved immune checkpoint blockers. Specific aspects of pharmacological development, as well as attempts to personalize cancer treatments using patient-derived xenografts, require the development of mouse models in which murine genes and cells are replaced with their human equivalents. Such 'humanized' mouse models are being progressively refined to characterize the leukocyte subpopulations that belong to the innate and acquired arms of the immune system as they infiltrate human cancers that are subjected to experimental therapies. We surmise that the ever-advancing refinement of murine preclinical models will accelerate the pace of therapeutic optimization in patients.
Collapse
Affiliation(s)
- Laurence Zitvogel
- Gustave Roussy Cancer Campus (GRCC), INSERM U1015, 114 rue Edouard Vaillant, 94805 Villejuif, France
- Center of Clinical Investigations in Biotherapies of Cancer, CICBT1428, GRCC, 94805 Villejuif, France
| | - Jonathan M Pitt
- Gustave Roussy Cancer Campus (GRCC), INSERM U1015, 114 rue Edouard Vaillant, 94805 Villejuif, France
| | - Romain Daillère
- Gustave Roussy Cancer Campus (GRCC), INSERM U1015, 114 rue Edouard Vaillant, 94805 Villejuif, France
| | - Mark J Smyth
- QIMR Berghofer Medical Research Institute, Herston, QLD, Australia; University of Queensland, Herston, QLD, Australia
| | - Guido Kroemer
- Equipe 11 labelisée par la Ligue Nationale contre le Cancer, INSERM U1138, Centre de Recherche des Cordeliers, 75006 Paris, France
- University of Paris Descartes, Sorbonne Paris Cité, 75006 Paris, France
- University of Pierre et Marie Curie, 75006 Paris, France
- Pôle de Biologie, Hôpital Européen Georges Pompidou, 75015 Paris, France
- Metabolomics and Cell Biology Platforms, GRCC, 94805 Villejuif, France
- Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, 17176 Stockholm, Sweden
| |
Collapse
|
117
|
Caldemeyer L, Akard LP. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia. Leuk Lymphoma 2016; 57:2739-2751. [DOI: 10.1080/10428194.2016.1198959] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
|